Summary
The nephrotoxic potential of alpha-interferon (IFN alpha-2b) was analysed in 21 patients with chronic myeloid leukemia. As particularly sensitive parameters in the detection of subclinical renal injury we measured the excretion of the following urinary enzymes: lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT), leucine arylaminidase (LAP), β-galactosidase (GAL) and N-acetyl-beta-glucosaminidase (NAG). Additionally, protein excretion and urinary sediment were analysed. In 18 of 21 patients a significant increase in the excretion of LDH, LAP, GGT and NAG was found, in 6 patients there was an additional rise in the output of GAL. Eleven patients developed proteinuria up to 2 g/l, one patient excreted up to 9 g/l. Enzymuria and protein excretion decreased in all patients after reduction of the IFN alpha-2b dosage and disappeared in two patients following cessation of therapy. The high incidence of nephrotoxic events in patients with CML during IFN alpha-2b therapy might be mostly due to immunological or substance-specific effects.
Similar content being viewed by others
Abbreviations
- CML:
-
chronische myeloische Leukämie
- GAL:
-
Beta-Galactosidase
- GGT:
-
Gamma-Glutamyltransferase
- IFN alpha-2b:
-
Interferon alpha-2b
- LAP:
-
Leucinarylamidase
- LDH:
-
Laktatdehydrogenase
- NAG:
-
N-Acetylbeta-Glucosaminidase
- SD:
-
Standardabweichung
- \(\bar X\) :
-
Mittelwert
Literatur
Abdulhay G, DiSaia PJ, Blessing JA, Creasman WT (1985) Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: Gynecologic Oncology Group study: Am J Obstet Gynecol 152:418–423
Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, Morel-Maroger L (1980) The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 40:373–382
Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, Longo DL (1984) Acute interstitial nephritis with the nephrotic syndrome following recombinant leucocyte A interferon therapy for mycosis fungoides. N Engl J Med 310:32–35
Bunn P, Foon K, Ihde D, Longo DL, Winkler C, Zeffren J, Oldham R, Sherwin S (1984) Recombinant leucocyte A interferon (IFL-RA) in the treatment of advanced refractory cutaneous T-cell-lymphomas (CTCL). Proc Am So Clin Oncol 3:52
Costanzi JJ, Cooper MR, Scarffe JH, Ozer H, Grubbs SS, Ferraresi RW, Pollard RB, Spiegel RJ (1985) Phase II-study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 3:654–659
Foon KA (1986) Recombinant leucocyte interferon A therapy for advanced hariy cell leukemia. Am J Med 80:351–356
Görg A, Postel W, Westermeier R, Gianazza E, Righette PG (1980) SDS-Gradienten Gelelektrophorese in horizontalen dünnen Gelen. J Biochem Biophys Meth 3:273–284
Hooks JJ, Moutsopoulos HM, Notkins AL (1980) The role of interferon in immediate hypersensitivity and autoimmune diseases. Ann NY Acad Sci 80:21–32
Killen PA, Melcion C, Bonadio JF, Morel-Maroger L, Striker GE (1982) Glomerular response to immunologic injury, studies on progression. Springer Semin Immunopathol 5:297–320
Kramer P, Ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W (1984) Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1:989–990
Maruhn D, Fuchs I, Mues G, Bock KD (1976) Normal limits of urinary excretion of eleven enzymes. Clin Chem 22:1567–1574
Morel-Maroger L, Verroust P, Woodrow D (1980) Role of interferon in murine glomerulonephritis. In: Leaf A, Giebisch G, Bolis L, Gorini S (eds) Renal Pathophysiology — Recent Advances. Raven Press, New York; pp 9–16
Niederle N, Schmidt CG (1985) Klinische Erfahrungen mit Interferon in der Tumortherapie. In: Schuff-Werner P, Pfizenmaier K (Hrsg): Entwicklung, Prüfung und Anwendung von biologisch aktiven Substanzen in der Krebstherapie. Zuckschwert, München Bern Wien (Aktuelle Onkologie, 24; S 116–136)
Niederle N, Kloke O, Nowrousian MR, Kruse H, Schmidt CG (1986) Efficacy of gamma- and alpha-interferon in the treatment of hairy cell leukemia. J Cancer Res Clin Oncol 111 (Suppl):40
Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG (1986) Alpha-2-Interferon: Erste Behandlungsergebnisse bei der chronischen myeloischen Leukämie. Dtsch Med Wochenschr 111:767–772
Quesada JR, Reuben J, Manning JT, Hersh EM, Guttermann JU (1984) Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310:15–18
Ronco P, Woodrow D, Riviere Y, Moss J, Verroust P, Guillon JC, Gresser I, Sloper JC, Morel-Maroger L (1980) Further studies on the inhibition of lymphocytic choriomeningitis-induced glomerulonephritis by antiinterferon globulin. Lab Invest 43:37–46
Scherberich JE, Mondorf WA (1983) Beurteilung der Nephrotoxizität von Pharmaka über die Ausscheidung tubulusspezifischer Membranantigene und Enzyme. Z ges inn Med 21:571–580
Selby P, Kohn J, Raymond J, Judson I, McElwain T (1985) Nephrotic syndrome during treatment with interferon. Br Med J 290:1180
Sriskandan K, Tee DEH, Pettingale KW (1985) Nephrotic syndrome during treatment with interferon. Br Med J 290:1590–1591
Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leucocyte interferon-induced myeloid cytoreduction in chronic myeloid leukemia. Blood 52:689–692
Talpaz M, Trujillo JM, Hittelman WN, Keating MJ, Gutterman JU (1985) Suppression of clonal evolution in two chronic myeloid leukemia patients treated with leucocyte interferon. Br J Haematol 60:619–624
Woodrow D, Ronco P, Riviere Y, Moss J, Gresser I, Guillon JC, Morel-Maroger L, Sloper JC, Verroust P (1982) Severity of glomerulonephritis induced in different strains of suckling mice by infection with lymphocytic choriomeningitis virus: Correlation with amounts of endogenous interferon and circulating immune complexes. J Path 138:325–336
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kurschel, E., Metz-Kurschel, U., Hofmann, W. et al. Untersuchungen zur Erfassung der Nephrotoxizität von humanem Alpha-2b-Interferon unter besonderer Berücksichtigung der Analyse von Harnenzymen bei Patienten mit chronischer myeloischer Leukämie. Klin Wochenschr 65, 667–672 (1987). https://doi.org/10.1007/BF01875502
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01875502